Last reviewed · How we verify

natalizumab (NTZ) — Competitive Intelligence Brief

natalizumab (NTZ) (natalizumab (NTZ)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (integrin antagonist). Area: Immunology / Neurology.

marketed Monoclonal antibody (integrin antagonist) α4β1 integrin (VLA-4) Immunology / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

natalizumab (NTZ) (natalizumab (NTZ)) — University Hospital, Clermont-Ferrand. Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
natalizumab (NTZ) TARGET natalizumab (NTZ) University Hospital, Clermont-Ferrand marketed Monoclonal antibody (integrin antagonist) α4β1 integrin (VLA-4)
BG00002 (natalizumab) BG00002 (natalizumab) Biogen marketed Monoclonal antibody (integrin antagonist) α4β1 integrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (integrin antagonist) class)

  1. Biogen · 1 drug in this class
  2. University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). natalizumab (NTZ) — Competitive Intelligence Brief. https://druglandscape.com/ci/natalizumab-ntz. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: